Maternal and Infant Immunity: Current Trends in Vaccinology

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Clinical Immunology".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 3015

Special Issue Editors


E-Mail Website
Guest Editor
Boston Children's Hospital, Boston, MA, USA
Interests: neonatal immune ontogeny; neonatal sepsis; antimicrobial stewardship; use of antibiotics or vaccines to alter outcomes to neonatal sepsis; vaccine correlates of protection; transplacental transfer of antibodies

E-Mail
Guest Editor
London School of Hygiene & Tropical Medicine, London, UK
Interests: early life vaccines; mucosal vaccines; contextual issues in vaccinology (immune ontogeny, impact of sepsis, and impact of epidemiology on vaccine responses); clinical trials

E-Mail Website
Guest Editor
Beth Israel Deaconess Medical Center, Boston Children's Hospital, Boston, MA, USA
Interests: trained immunity; newborn innate immune ontogeny and the role of vaccine-induced "heterologous protection" against unrelated pathogens; systems biology; biomarkers; vaccine clinical trials

E-Mail Website
Guest Editor
Boston Children's Hospital, Boston, MA, USA
Interests: mother–infant dyad; immune ontogeny; early life vaccines; innate immune response; vaccine adjuvants; maternal immune transfer; pregnancy; vaccine clinical trials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neonatal, infant, and maternal morbidity and mortality remain a significant global health concern. Neonatal immune system development starts in utero and is characterized by a Th2 predominance, which promotes a pro-tolerogenic response that enables the delivery of a viable fetus. The infant immune system is shaped by both intrauterine exposures (e.g., maternal immunity and vaccines) and the postnatal environment. Although the details of immunological control/suppression or the inflammatory response throughout pregnancy remain poorly characterized, it is known that certain infectious, inflammatory, and autoimmune conditions alter the maternal immune system. Transplacental transfer of maternal antibodies provides some protection to neonates and may also affect the infants’ immune response to vaccines. Therefore, successful neonatal and maternal immunization requires an adequate understanding of the immunology of the maternal–fetal interface, immune ontogeny, the effect of different pregnancy states on maternal/fetal immune ontogeny, and correlates of vaccine-induced protection.

In this Special Issue, we invite authors to submit original research articles or reviews that focus on the following topics:

  • Studies on the immunology of the maternal-fetal interface as it applies to vaccine development.
  • Studies that examine how the pregnant immune system is altered by maternal immunization, infection, inflammation, or autoimmune states, including post-partum-specific considerations regarding vaccine development and maternal/neonatal immunizations.
  • Studies that identify correlates of vaccine-induced protection, including neonatal/infant and maternal immunizations.
  • Studies on preventative vaccines that impact newborns, children under the age of five, and pregnancy-related morbidity and mortality, including registered and non-registered clinical trials.

Dr. Oludare A. Odumade
Dr. Olubukola T. Idoko
Dr. Asimenia Angelidou
Dr. Kinga K. Smolen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adaptive immunity
  • innate immunity
  • immunization
  • infant
  • maternal
  • newborn
  • omics
  • vaccine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 245 KiB  
Review
Maternal Vaccination for the Prevention of Infantile RSV Disease: An Overview of the Authorized, In-Progress, and Rejected Vaccine Candidates
by Georgios Papazisis and Xanthippi Topalidou
Vaccines 2024, 12(9), 980; https://doi.org/10.3390/vaccines12090980 - 28 Aug 2024
Cited by 1 | Viewed by 2629
Abstract
Respiratory Syncytial Virus (RSV) continues to pose a significant challenge, contributing to elevated hospitalization rates among children up to 5 years old, with a disproportionate burden on newborns and infants under 6 months old. The unique characteristics of the young immune system make [...] Read more.
Respiratory Syncytial Virus (RSV) continues to pose a significant challenge, contributing to elevated hospitalization rates among children up to 5 years old, with a disproportionate burden on newborns and infants under 6 months old. The unique characteristics of the young immune system make it prone to altered responses to infections and vaccinations, requiring a tailored approach to disease prevention. The recent approval of the maternal RSV vaccine (brand name ABRYSVO) represents a pivotal advancement in preventive strategies among newborns and infants, marking a milestone in RSV research as the first market-approved maternal vaccine. The present review examines clinical trial data on both recent and previous vaccine candidates, as well as the licensed vaccine, focusing on the prevention of RSV disease in newborns and young infants through the passive acquisition of antibodies following maternal immunization. Additionally, it evaluates the safety profile of these vaccines. Full article
(This article belongs to the Special Issue Maternal and Infant Immunity: Current Trends in Vaccinology)
Back to TopTop